000125795 001__ 125795
000125795 005__ 20240228143332.0
000125795 0247_ $$2doi$$a10.18632/oncotarget.6459
000125795 0247_ $$2pmid$$apmid:26646792
000125795 0247_ $$2pmc$$apmc:PMC4811493
000125795 0247_ $$2altmetric$$aaltmetric:4863670
000125795 037__ $$aDKFZ-2017-01919
000125795 041__ $$aeng
000125795 082__ $$a610
000125795 1001_ $$aFahiminiya, Somayyeh$$b0
000125795 245__ $$aMolecular analyses reveal close similarities between small cell carcinoma of the ovary, hypercalcemic type and atypical teratoid/rhabdoid tumor.
000125795 260__ $$a[S.l.]$$bImpact Journals LLC$$c2016
000125795 3367_ $$2DRIVER$$aarticle
000125795 3367_ $$2DataCite$$aOutput Types/Journal article
000125795 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521727024_2109
000125795 3367_ $$2BibTeX$$aARTICLE
000125795 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125795 3367_ $$00$$2EndNote$$aJournal Article
000125795 520__ $$aSmall cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is the most common undifferentiated ovarian malignancy diagnosed in women under age 40. We and others recently determined that germline and/or somatic deleterious mutations in SMARCA4 characterize SCCOHT. Alterations in this gene, or the related SWI/SNF chromatin remodeling gene SMARCB1, have been previously reported in atypical teratoid/rhabdoid tumors (ATRTs) and malignant rhabdoid tumors (MRTs). To further describe the somatic landscape of SCCOHT, we performed whole exome sequencing on 14 tumors and their matched normal tissues and compared their genomic alterations with those in ATRT and ovarian high grade serous carcinoma (HGSC). We confirmed that SMARCA4 is the only recurrently mutated gene in SCCOHT, and show that recurrent allelic imbalance is observed exclusively on chromosome 19p, where SMARCA4 resides. By comparing genomic alterations between SCCOHT, ATRT and HGSC, we demonstrate that SCCOHTs, like ATRTs, have a remarkably simple genome and harbor significantly fewer somatic protein-coding mutations and chromosomal alterations than HGSC. Furthermore, a comparison of global DNA methylation profiles of 45 SCCOHTs, 65 ATRTs, and 92 HGSCs demonstrates a strong epigenetic correlation between SCCOHT and ATRT. Our results further confirm that the genomic and epigenomic signatures of SCCOHT are more similar to those of ATRT than HGSC, supporting our previous hypothesis that SCCOHT is a rhabdoid tumor and should be renamed MRT of the ovary. Furthermore, we conclude that SMARCA4 inactivation is the main cause of SCCOHT, and that new distinct therapeutic approaches should be developed to specifically target this devastating tumor.
000125795 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000125795 588__ $$aDataset connected to CrossRef, PubMed,
000125795 650_7 $$2NLM Chemicals$$aNuclear Proteins
000125795 650_7 $$2NLM Chemicals$$aTranscription Factors
000125795 650_7 $$0EC 3.6.1.-$$2NLM Chemicals$$aSMARCA4 protein, human
000125795 650_7 $$0EC 3.6.4.-$$2NLM Chemicals$$aDNA Helicases
000125795 7001_ $$aWitkowski, Leora$$b1
000125795 7001_ $$aNadaf, Javad$$b2
000125795 7001_ $$aCarrot-Zhang, Jian$$b3
000125795 7001_ $$aGoudie, Catherine$$b4
000125795 7001_ $$aHasselblatt, Martin$$b5
000125795 7001_ $$aJohann, Pascal$$b6
000125795 7001_ $$0P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aKool, Marcel$$b7$$udkfz
000125795 7001_ $$aLee, Ryan S$$b8
000125795 7001_ $$aGayden, Tenzin$$b9
000125795 7001_ $$aRoberts, Charles W M$$b10
000125795 7001_ $$aBiegel, Jaclyn A$$b11
000125795 7001_ $$aJabado, Nada$$b12
000125795 7001_ $$aMajewski, Jacek$$b13
000125795 7001_ $$aFoulkes, William D$$b14
000125795 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.6459$$gVol. 7, no. 2, p. 1732 - 1740$$n2$$p1732 - 1740$$tOncoTarget$$v7$$x1949-2553$$y2016
000125795 909CO $$ooai:inrepo02.dkfz.de:125795$$pVDB
000125795 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000125795 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000125795 9141_ $$y2016
000125795 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bONCOTARGET : 2015
000125795 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125795 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125795 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125795 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125795 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125795 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125795 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000125795 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bONCOTARGET : 2015
000125795 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lPädiatrische Neuroonkologie$$x0
000125795 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x1
000125795 980__ $$ajournal
000125795 980__ $$aVDB
000125795 980__ $$aI:(DE-He78)B062-20160331
000125795 980__ $$aI:(DE-He78)L101-20160331
000125795 980__ $$aUNRESTRICTED